INBRAIN Neuroelectronics funding news -Graphene-based INBRAIN Neuroelectronics Secures $50 Million in Series B Round Funding

The round was led by imec.xpand, with new investors like the EIC Fund, Fond ICO Next Tech, CDTI-Innvierte, and Avançsa joining existing investors Asabys Partners, Aliath Bioventures, and Vsquared. This brings the total funding since the company started to $68 million.

This funding will help INBRAIN speed up the development of its graphene-based BCI-Tx platform, which can decode and modulate brain activity with high precision. It will support ongoing clinical trials, help expand the team, and further develop their AI-driven platform for treating neurological diseases.

Read also - Oriole Networks funding news – London-based Oriole Networks Secures an Additional €20.2 Million Funding

Collaborations for Growth

INBRAIN has also received additional funding from Merck KGaA to further develop its technology in areas of interest to Merck. This partnership aims to translate INBRAIN’s platform for use in humans expanding its applications in both central and peripheral nervous systems.

The company is working with imec, a leading nanoelectronics hub, to help scale its graphene interfaces for commercial use.

Helping Patients Regain Function

INBRAIN’s neural platform maximizes therapy time and effectively helps restore function or mobility for patients. Its BCIs are skin-like, bi-directional, and have up to 1024 contacts, allowing for real-time neural decoding and modulation. The implantable processor is compact and rechargeable wirelessly.

First Human Application

Recently, INBRAIN achieved a significant milestone with the world’s first human application of its graphene-based BCI in a clinical trial at Salford Royal Hospital in Manchester, UK. This trial is assessing the safety of the device in brain cancer patients and will include up to ten participants to compare graphene’s effectiveness with traditional materials.

Carolina Aguilar, CEO and Co-Founder of INBRAIN Neuroelectronics said, “We’re shaping the future of brain-computer interface therapeutics, This funding empowers us to advance our AI-driven graphene neurotechnology, which has already shown great results versus current commercial neuromodulation technology. We are excited to have the support of a top-tier syndicate as we work to bring this technology to patients in need of more precise, personalised treatments.”

Frank Bulens, Partner at imec.xpand said, “INBRAIN Neuroelectronics is pioneering a groundbreaking approach to BCI technology using graphene, This unique graphene-based BCI platform has the potential to redefine how we treat neurological disorders by offering more precise, adaptable, and intelligent therapeutics. We look forward to supporting the INBRAIN team in accelerating their clinical trials and bringing this next-generation technology to patients.”

Marcin Nowak, Investment Director at European Investment Bank said, “The success of INBRAIN’s first patient procedure and recent funding highlights the innovation we envisioned when we launched the Graphene Flagship project, By harnessing the remarkable properties of graphene, INBRAIN is advancing cutting-edge neurotechnology applications that could significantly improve patient outcomes and also position Europe as one of the leaders in the global BCI industry. With this important investment, we are proud to support INBRAIN in translating this technology from research into real-world impact on patients’ lives.”

About INBRAIN Neuroelectronics

INBRAIN Neuroelectronics is leading the way in precision neurology with its groundbreaking graphene-based brain-computer interface platform. Their technology combines advanced neural decoding and modulation to provide personalized treatments for conditions like Parkinson’s, epilepsy, and stroke rehabilitation continuously monitoring and adjusting therapies to enhance patient outcomes while minimizing side effects.